The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Side-by-side photos from 2019 and 2025 make Rebel Wilson's facial transformation after shedding over 80 pounds strikingly apparent. Noticeable changes include reduced volume, minor skin elasticity loss in cheeks, neck, and around lips and eyes, plus a sharper jawline. While many attribute it to Ozempic, Wilson clarifies its limited role in her journey.
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
Sydney's superstar chef Neil Perry, behind Gran Torino, Margaret, and Qantas menus, isn't fazed by the Ozempic craze. He pledges to continue creating beautiful food for those who love to eat. In a bold GLP-1 warning, Perry hints at potential lawsuits ahead.
Trey Luker-Stewart lost 60 pounds on Ozempic, but it transformed his drinking from fun nights to anxious, emotional ones with brutal hangovers. As a Dallas bar owner, he's seen a 35% drop in alcohol sales linked to GLP-1 drugs. Doctors reveal why these medications blunt alcohol's rewards and worsen next-day effects.
South African DJ Shimza set the record straight on Podcast and Chill, firmly denying rumors that his impressive weight loss came from Ozempic or that he profits from government tenders. With his partner Athi Geleba in a high-profile Presidency position, speculation ran wild—but Shimza insists he earns his money through hard work. This candid interview sheds light on celebrity health rumors and tender controversies.
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
This awards season, Hollywood red carpets showcase pin-thin silhouettes from Emma Stone to Jenna Ortega, fueled by Ozempic microdosing. Stylists fear stars are unaware of their extreme thinness, while nutritionists spot muscle wasting and malnutrition signs. As body positivity fades, insiders reveal the pressure and health toll.
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
